<DOC>
	<DOCNO>NCT00413894</DOCNO>
	<brief_summary>This single arm study ass efficacy safety intravenous Mircera , administer pre-filled syrinx , treatment anemia patient chronic kidney disease dialysis , previously receive treatment epoetin alfa beta darbepoetin alfa . Patients receive monthly intravenous injection Mircera , start dose derive dose epoetin alfa beta darbepoetin receive week precede study start . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Intravenous Mircera Treatment Anemia Dialysis Patients .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia ; longterm hemodialysis &gt; =12 week screen ; baseline Hb 10 13g/dL ; iv sc maintenance epoetin alfa beta darbepoetin alfa therapy dose interval &gt; =4 week screen . acute chronic bleeding within 8 week prior screen ; transfusion red blood cell within 8 week prior screen ; poorly control hypertension necessitate interruption erythropoetin treatment previous 6 month ; previous treatment Mircera .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>